Stock Analysis
- United States
- /
- Life Sciences
- /
- NasdaqGS:MLAB
3 US Stocks Trading Below Estimated Value
Reviewed by Simply Wall St
As U.S. markets experience a slight pullback following recent record highs, investors are keenly watching how upcoming inflation data might influence Federal Reserve decisions. Amidst this backdrop, identifying stocks trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market fluctuations and economic indicators.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
Name | Current Price | Fair Value (Est) | Discount (Est) |
NBT Bancorp (NasdaqGS:NBTB) | $50.26 | $99.93 | 49.7% |
UMB Financial (NasdaqGS:UMBF) | $123.67 | $243.25 | 49.2% |
Hims & Hers Health (NYSE:HIMS) | $32.63 | $64.70 | 49.6% |
West Bancorporation (NasdaqGS:WTBA) | $23.32 | $46.38 | 49.7% |
Business First Bancshares (NasdaqGS:BFST) | $28.19 | $54.93 | 48.7% |
Equity Bancshares (NYSE:EQBK) | $47.26 | $92.07 | 48.7% |
U.S. Physical Therapy (NYSE:USPH) | $96.50 | $187.03 | 48.4% |
Vasta Platform (NasdaqGS:VSTA) | $2.18 | $4.31 | 49.4% |
First Advantage (NasdaqGS:FA) | $20.00 | $39.00 | 48.7% |
Marcus & Millichap (NYSE:MMI) | $41.51 | $81.04 | 48.8% |
Here we highlight a subset of our preferred stocks from the screener.
Open Lending (NasdaqGM:LPRO)
Overview: Open Lending Corporation offers lending enablement and risk analytics solutions to credit unions, regional banks, finance companies, and automaker captive finance companies in the United States, with a market cap of approximately $742.36 million.
Operations: The company generates revenue from its Internet Information Providers segment, amounting to $95.89 million.
Estimated Discount To Fair Value: 43.5%
Open Lending is trading at US$6.22, significantly below its estimated fair value of US$11.02, highlighting potential undervaluation based on cash flows. Despite a decline in recent earnings and profit margins, the company's earnings are projected to grow substantially at 71.5% annually over the next three years, outpacing the broader US market's growth rate. Recent strategic partnerships aim to enhance loan processing efficiency for near- and non-prime borrowers, potentially boosting future revenue streams amidst stabilizing vehicle registration trends.
- The growth report we've compiled suggests that Open Lending's future prospects could be on the up.
- Get an in-depth perspective on Open Lending's balance sheet by reading our health report here.
Mesa Laboratories (NasdaqGS:MLAB)
Overview: Mesa Laboratories, Inc. is a company that develops, designs, manufactures, sells, and services life sciences tools and quality control products globally with a market cap of $673.50 million.
Operations: The company's revenue segments include Clinical Genomics ($46.57 million), Calibration Solutions ($49.04 million), Biopharmaceutical Development ($45.49 million), and Sterilization and Disinfection Control ($87.28 million).
Estimated Discount To Fair Value: 27.5%
Mesa Laboratories is trading at US$131.06, significantly below its estimated fair value of US$180.89, suggesting it may be undervalued based on cash flows. The company reported a net income of US$3.43 million for the recent quarter, reversing a loss from the previous year and demonstrating strong earnings growth potential with forecasts indicating profitability over the next three years. Despite slower revenue growth compared to the market, Mesa's financial health remains robust with a high forecasted return on equity.
- According our earnings growth report, there's an indication that Mesa Laboratories might be ready to expand.
- Click to explore a detailed breakdown of our findings in Mesa Laboratories' balance sheet health report.
Smartsheet (NYSE:SMAR)
Overview: Smartsheet Inc. offers an enterprise platform designed to plan, capture, manage, automate, and report on work for teams and organizations, with a market cap of approximately $7.85 billion.
Operations: The company generates revenue of $1.08 billion from its Internet Software & Services segment.
Estimated Discount To Fair Value: 43.3%
Smartsheet, trading at US$56.08, is valued below its estimated fair value of US$98.85, indicating potential undervaluation based on cash flows. The company recently reported a net income of US$1.32 million for the third quarter, transitioning from a loss in the previous year. Despite shareholder dilution and slower revenue growth compared to peers, Smartsheet's forecasted profitability and high return on equity highlight its financial appeal amid ongoing acquisition discussions valuing it at US$8.4 billion.
- Upon reviewing our latest growth report, Smartsheet's projected financial performance appears quite optimistic.
- Dive into the specifics of Smartsheet here with our thorough financial health report.
Next Steps
- Unlock more gems! Our Undervalued US Stocks Based On Cash Flows screener has unearthed 187 more companies for you to explore.Click here to unveil our expertly curated list of 190 Undervalued US Stocks Based On Cash Flows.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:MLAB
Mesa Laboratories
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.